Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Haleon PLC ( (GB:HLN) ) has issued an announcement.
Haleon has published its 2025 Annual Report and Accounts and Form 20-F, along with the notice of its 2026 Annual General Meeting, making these documents available on its corporate website and through relevant regulatory storage mechanisms in the U.K. and U.S. The company’s AGM will again be held as a virtual meeting on 29 April 2026 at 3:00 p.m. BST, with shareholders able to access detailed business information, voting materials and request free hard copies of the full audited report, underscoring Haleon’s ongoing focus on transparency and accessibility for investors.
The filings with the U.S. Securities and Exchange Commission and submission to the U.K.’s National Storage Mechanism ensure Haleon meets cross‑market disclosure and listing requirements, reinforcing its compliance posture as a dual‑listed issuer. By maintaining a virtual AGM format and clearly outlining participation and proxy arrangements, the company is seeking to facilitate broader shareholder engagement while streamlining governance processes across its global investor base.
The most recent analyst rating on (GB:HLN) stock is a Buy with a £450.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Spark’s Take on GB:HLN Stock
According to Spark, TipRanks’ AI Analyst, GB:HLN is a Neutral.
The score is driven primarily by solid financial performance (consistent free cash flow and improving profitability) and a cautiously positive earnings outlook supported by margin gains and cost savings. This is tempered by weaker near-term technical momentum and only moderate valuation support.
To see Spark’s full report on GB:HLN stock, click here.
More about Haleon PLC
Haleon plc (LSE/NYSE: HLN) is a consumer health company focused on improving everyday health through a broad portfolio across oral health, vitamins, minerals and supplements, pain relief, respiratory and digestive health, and therapeutic skin health. Its leading brands, including Sensodyne, Panadol, Advil, Voltaren and Centrum, reach more than one billion consumers and are widely recommended by health professionals worldwide.
Average Trading Volume: 18,282,319
Technical Sentiment Signal: Sell
Current Market Cap: £33.23B
For a thorough assessment of HLN stock, go to TipRanks’ Stock Analysis page.